

Design and evaluation of EphrinA1 mutants with cerebral protective effect

Yuanjun Zhu^{1,#}, Yuanqing Gao^{1,#}, Danping Zheng^{1,#}, Mengyang Shui¹, Kuai Yu¹, Xiaoyan liu¹, Yuan Lin², Li Su³, Wenxing Yang⁴, Yinye Wang¹

¹ Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing, China

² State Key Laboratory of Bioactive Substances and Function of Natural Medicine, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

³ Center of Medical and Health Analysis, Peking University Health Science Center, Beijing, China

⁴ Department of Organismic and Evolutionary Biology, Center for Brain Science, Harvard University, Cambridge, MA, USA

Correspondence and requests for materials should be addressed to Y.W. (wangyinye@bjmu.edu.cn) or Y.Z. (zhuyuanjun@bjmu.edu.cn).

[#] These authors contributed equally to this work.




Figure S1. Generation of the EphrinA1 mutants. (A) Expression of recombinant proteins EM1, EM2, EM3 and EM4 from bacteria. *E. coli* BL21(DE3) cells with expression plasmids were induced as described in Methods. These proteins were expressed in inclusion bodies, as indicated by the arrows. (B) Purified EM2 and EM4 proteins using Ni-NTA affinity chromatography.